The effect of empagliflozin on peripheral microvascular dysfunction in patients with heart failure with preserved ejection fraction

Table 4 Health changes after 3 months of empagliflozin according to the Paretian classification of health change (PCHC)

Patients who reported the same classification of health at baseline and 3 months follow-up were represented as ‘no change’. Patients who never reported any health problems were represented as ‘no problems’. Patients who did not consistently improve or worsen on all aspects of the classification were represented as ‘Mixed change’

ISSN: 1475-2840